Inextron Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the plate, announced today that it will refocus the company on healthcare, change its name to Precigen, Inc. and, effective immediately, has appointed Helen Sabzevari, PhD, as President and CEO.
SIOUX CENTER, Iowa, July 8, 2019
National Center for Advancing Translational Sciences supports generation, characterization of a MiniSwine model of Sickle Cell Disease, to support life changing research for patients.
Dalmose, Denmark, 26 November 2018
Ellegaard Göttingen Minipigs A/S, today announced the signing of a license and commercialization agreement with Exemplar Genetics to develop and commercialize genetically modified Göttingen Minipigs models of human disease on a target-by-target basis. Göttingen Minipigs are a small, docile, microbiologically and genetically well-defined large animal model recognized by the global biomedical research community and regulatory authorities, making Göttingen Minipigs the genetics of choice for preclinical studies.
Original research article published on April 18, 2018 in Circulation.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.032184 Circulation. 2018;CIRCULATIONAHA.117.032184
Download PDF from Circulation here
SIOUX CENTER, Iowa, April 16, 2018
Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) committed to enabling the study of life-threatening human diseases, today announced two publication in the current issue of the Journal of Clinical Investigation (JCI) demonstrating the potential of ExeGen® CFTR MiniSwine research models to help define and develop effective gene therapies for cystic fibrosis.
Contact information:
P.O. Box 198 Sioux Center, IA 51250
Phone: 712-722-2767
Fax: 712-722-2126
General inquiries:
contact@exemplargenetics.com
Media inquiries:
media@exemplargenetics.com
AAALAC MEMBER
